This discussion focuses on the challenges of global drug development and the long-term implications of COVID-19.

Frontage supports early drug discovery with various immunoassays for proteins and therapeutic antibodies to support pharmacokinetics/toxicokinetics (PK/TK), pharmacodynamics (PD), and biomarkers analysis.

The human gut microbiome contains a complex aggregate of colonic bacterial enzymes mediating the metabolism of a wide range of xenobiotics and dietary components. This webinar highlights examples of pre-systematic drug clearance mediated by colonic enzymes contributing to systemic metabolite exposure, examines evidence of a causative link between dysbiosis and metabolic disorders, and concludes with an overview of established gut microbiome biomarkers and assay panels available to support investigations in understanding the metabolic fate of xenobiotics and colonic bacterial secondary metabolites.